Form 8-K

8-K — Aclarion, Inc.

Accession: 0001683168-26-003124

Filed: 2026-04-22

Period: 2026-04-21

CIK: 0001635077

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — aclarion_8k.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED APRIL 22, 2026 (aclarion_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: aclarion_8k.htm · Sequence: 1

Aclarion, Inc. 8-K

false

0001635077

2026-04-21

0001635077

ACON:CommonStockParValue0.00001PerShareMember

2026-04-21

0001635077

ACON:WarrantsEachExercisableForOneShareOfCommonStockMember

2026-04-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event

reported): April 21,

2026

Aclarion,

Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41358

47-3324725

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

8181 Arista Place, Suite 100

Broomfield, Colorado

80021

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (833) 275-2266

Not

Applicable

(Former name or former address, if changed since last report)

Check the appropriate box

below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock

ACON

Nasdaq Stock Market

Common

Stock Warrants

ACONW

Nasdaq Stock Market

Series D Junior Participating Preferred Purchase Rights

N/A

Nasdaq Stock Market

Indicate by check mark whether

the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule

12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company,

indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial

accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 21, 2026, the board of directors

of Aclarion, Inc. (the “Company”) authorized and approved a share repurchase program. Under the share repurchase program,

the Company may repurchase up to $2.5 million in value of the Company’s outstanding shares of common stock from time to time over

the next 12 months. The Company may buy back its common stock from time to time, in amounts, at prices, and at such times as the Company

deems appropriate, subject to market conditions, pursuant to Rule 10b-18 of the Securities Exchange Act of 1934, as amended, and federal

and state laws governing such transactions, through a variety of methods, which may include open market purchases, privately negotiated

transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of

such methods. The share repurchase program does not oblige the Company to acquire any specific number of shares and may be modified, discontinued,

or suspended at any time.

On April 22, 2026, the Company issued a press

release announcing the authorization of the share repurchase program. A copy of the press release is attached to this Current Report on

Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press Release, dated April 22, 2026

104

Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACLARION, INC.

April 22, 2026

By:

/s/ Gregory A. Gould

Name:

Gregory A. Gould

Title:

Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED APRIL 22, 2026

EX-99.1

Filename: aclarion_ex9901.htm · Sequence: 2

Exhibit 99.1

Aclarion Announces

$2.5 Million Stock Repurchase Plan

Highlights Disciplined

Capital Allocation While Supporting Continued Nociscan® Adoption

Broomfield, CO, April 22, 2026 – Aclarion,

Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare

technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan platform to help

physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that its Board

of Directors has authorized a share repurchase program of up to $2.5 million of the Company’s outstanding common stock.

Aclarion expects to execute the repurchase program over the next 12

months. The timing, volume, and nature of repurchases will be determined by the Company based on factors including market conditions,

share price, liquidity, and operational and strategic priorities. The program does not obligate the Company to acquire any specific number

of shares, and may be suspended, modified, or discontinued at any time.

The Company intends to fund the repurchase program using existing cash

and cash equivalents.

“This authorization underscores our commitment to disciplined

capital allocation and our belief that Aclarion’s current valuation does not fully reflect the strength of our platform and long-term

growth opportunity,” said Brent Ness, Chief Executive Officer of Aclarion. “We believe our shares represent a compelling value

at current levels, and we view this program as a flexible and opportunistic tool to enhance shareholder value while continuing to invest

in the clinical adoption and expansion of Nociscan.”

As of March 31, 2026, the Company had cash and cash equivalents of

approximately $19.0 million, which management believes provides sufficient runway to support operations through key upcoming milestones,

including the initial milestone of the CLARITY randomized trial.

Greg Gould, Chief Financial Officer of Aclarion, added, “We are

focused on balancing investment in growth with prudent capital management. Given our current capital position and expected operating needs,

we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility

necessary to execute on our strategic priorities.”

Repurchases under the program may be made from time to time, in amounts,

at prices, and at such times as the Company deems appropriate, subject to market conditions and other considerations, in compliance with

applicable federal and state securities laws, including Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, as amended.

Repurchases may be executed through a variety of methods, including open market purchases, privately negotiated transactions, block trades,

accelerated share repurchase transactions, or pursuant to Rule 10b5-1 trading plans, which may permit the Company to repurchase shares

during periods when it would otherwise be restricted from doing so.

For more News from Aclarion, please visit: Latest

News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company

that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented

intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan,

the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the

lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar

disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to

be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When

used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians

clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements

that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions,

are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are

subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as

well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements

regarding the expectation to execute the repurchase program over the next 12 months, that the Company intends to fund the repurchase program

using existing cash and cash equivalents, management’s belief that the $19.0 million at March 31, 2026 provides sufficient runway

to support operations through key upcoming milestones, including the initial milestone of the CLARITY randomized trial, and the potential

benefits of our Nociscan technology. These and other risks and uncertainties are discussed more fully in our filings with the Securities

and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual

Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings

made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and

the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,

future events or otherwise.

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim

SPRIG Consulting

jennie@sprigconsulting.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 21, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 21, 2026

Entity File Number

001-41358

Entity Registrant Name

Aclarion,

Inc.

Entity Central Index Key

0001635077

Entity Tax Identification Number

47-3324725

Entity Incorporation, State or Country Code

Entity Address, Address Line One

8181 Arista Place

Entity Address, Address Line Two

Suite 100

Entity Address, City or Town

Broomfield

Entity Address, State or Province

Entity Address, Postal Zip Code

80021

City Area Code

(833)

Local Phone Number

275-2266

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock Par Value 0. 00001 Per Share [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

ACON

Security Exchange Name

NASDAQ

Warrants Each Exercisable For One Share Of Common Stock [Member]

Title of 12(b) Security

Common

Stock Warrants

Trading Symbol

ACONW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=ACON_CommonStockParValue0.00001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=ACON_WarrantsEachExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: